Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?

Wednesday, February 27, 2019
Presented by: 
Eric Henry

Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss: 

  • The potential impact of biosimilars at this tipping point in the pharmaceutical industry 
  • FDA-required suffixes and standards for biosimilars naming 
  • Prescription workflow best practices for small and large molecule biosimilars 
  • Issues raised by retrospective naming and products without suffixes 

The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products.

You may also like:

Blog Post

For healthcare professionals recently, it seems like nearly every patient, customer at the pharmacy counter, and friend of your mother's has questions about the same thing. CBD oil. CBD...

View Blog Post
Blog Post

A recent GoodRx study found that more than 500 drugs saw price hikes of nearly 3% in the first quarter of 2019, according to an

View Blog Post
Blog Post

In a blog earlier this year, I discussed the Center for Medicare and Medicaid Services (CMS) Office of the Actuary’s estim...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up